Pulmonx Corporation (LUNG) Tops Q4 EPS by 4c; Offers Guidance

Pulmonx Corporation (NASDAQ: LUNG) reported Q4 EPS of ($0.38), $0.04 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $13.98 million.

GUIDANCE:

Pulmonx Corporation sees FY2023 revenue of $63-65 million, versus the consensus of $62.104 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Nucor projects Q3 2026 earnings above prior year, below estimates